Von Eschenbach Nomination Clears Committee But Faces Hurdles On Floor
This article was originally published in The Gray Sheet
Executive Summary
The Senate Health, Education, Labor & Pensions (HELP) Committee approved the nomination of FDA Acting Commissioner Andrew von Eschenbach as permanent commissioner and sent the nomination to the Senate floor Sept. 20
You may also be interested in...
Pushing von Eschenbach
Senate HELP Committee Chairman Michael Enzi (R-Wyo.) calls Nov. 16 for a lame-duck session floor vote to nominate FDA Acting Commissioner Andrew von Eschenbach to the permanent post. Incoming committee chair Edward Kennedy (D-Mass.) also supports the nomination. The same day, Senate Finance Committee Chairman Chuck Grassley (R-Iowa) placed a hold on von Eschenbach's nomination for his failure to comply with committee subpoenas. Fellow Republican Sens. David Vitter (La.) and Jim DeMint (S.C.) already have holds in place (1"The Gray Sheet" Sept. 25, 2006, p. 8)...
Pushing von Eschenbach
Senate HELP Committee Chairman Michael Enzi (R-Wyo.) calls Nov. 16 for a lame-duck session floor vote to nominate FDA Acting Commissioner Andrew von Eschenbach to the permanent post. Incoming committee chair Edward Kennedy (D-Mass.) also supports the nomination. The same day, Senate Finance Committee Chairman Chuck Grassley (R-Iowa) placed a hold on von Eschenbach's nomination for his failure to comply with committee subpoenas. Fellow Republican Sens. David Vitter (La.) and Jim DeMint (S.C.) already have holds in place (1"The Gray Sheet" Sept. 25, 2006, p. 8)...
Panel to vote on von Eschenbach
Senate Health Education Labor & Pensions Committee schedules Sept. 20 vote on nomination of Andrew von Eschenbach to be permanent FDA commissioner despite the prospect of future holds. Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.) have threatened to place holds on the nomination once it reaches the Senate floor due to the lack of a drug importation program and continued marketing of Danco Laboratories' abortion pill Mifeprex (mifepristone), respectively. Democratic Sens. Hillary Clinton (N.Y.) and Patty Murray (Wash.) only recently released their hold on the nominee following FDA's approval of Plan B for dual Rx/OTC status (1"The Gray Sheet" Aug. 28, 2006, In Brief)...